Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
News about Werewolf Therapeutics, Inc. (Nasdaq: HOWL) centers on its progress in developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Company announcements frequently highlight updates from its PREDATOR platform, which is used to design INDUKINE cytokine prodrugs and INDUCER T cell engager candidates that aim to stimulate adaptive and innate immunity while limiting systemic toxicity.
Investors and followers of HOWL can expect regular news on the clinical development of WTX-124 and WTX-330, Werewolf’s most advanced INDUKINE programs. Press releases describe Phase 1/1b and Phase 1b/2 trial updates in multiple advanced solid tumors, regulatory designations such as Fast Track status for WTX-124 in cutaneous melanoma after standard immunotherapy, and emerging data on tolerability, antitumor activity, and tumor-selective activation strategies.
News flow also covers the company’s expanding INDUCER T cell engager platform, including preclinical data for WTX-1011, an anti‑STEAP1 candidate for STEAP1-expressing cancers, and WTX-2022, targeting CDH6-expressing cancers. Werewolf reports on presentations at scientific and medical meetings, such as the Society for Immunotherapy of Cancer’s Annual Meeting and disease-focused summits, where it shares data on sequential dosing of IL‑12 and IL‑2 INDUKINE molecules, masking strategies to reduce cytokine release, and real-time pharmacokinetic insights.
Additional HOWL news items include quarterly financial results, business updates, conference participation, and partnering discussions around its broader INDUKINE portfolio, including WTX-712, WTX-518, and WTX-921. For readers tracking immuno-oncology developments, the Werewolf Therapeutics news page provides a consolidated view of clinical milestones, regulatory interactions, scientific presentations, and corporate strategy disclosures related to the company’s conditionally activated immune therapeutics.
Werewolf Therapeutics presented preclinical data on mWTX-330, an innovative IL-12 therapy, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer. The findings suggest mWTX-330 promotes significant anti-tumor activity and immune cell activation in the tumor microenvironment. Additionally, the FDA recently cleared the IND application for WTX-330, paving the way for clinical trials. This therapy aims to treat advanced solid tumors and lymphoma, potentially offering improved efficacy and safety over existing IL-12 therapies.
Werewolf Therapeutics (HOWL) announced significant advancements in its clinical pipeline, including the first patient dosed in a Phase 1/1b trial for WTX-124, targeting advanced solid tumors, with preliminary data expected in Q4 2023. The FDA granted IND clearance for WTX-330, aimed at treating relapsed/refractory tumors. The company reported a cash balance of $140.5 million, sufficient to fund operations through at least Q2 2024, alongside $5 million in collaboration revenue. Net loss for Q3 2022 was reduced to $11.9 million from $13.8 million YoY.
Werewolf Therapeutics (Nasdaq: HOWL) will present preclinical data on its IL-12 INDUKINE molecule, mWTX-330, at the Society for Immunotherapy of Cancer's 37th Annual Meeting on November 11, 2022. This research focuses on tumor-infiltrating lymphocytes and the tumor microenvironment in murine models. Additionally, the management team is set to engage in several investor conferences, including the Jefferies London Healthcare Conference on November 15 and the Piper Sandler Conference on November 29. These events aim to enhance investor relations and share insights into Werewolf's innovative cancer therapies.
Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available on-demand starting 7:00 AM EDT on September 12. Werewolf is focused on conditionally activated therapeutics that stimulate the immune system targeting cancer. Their leading candidates, WTX-124 and WTX-330, aim to improve treatment for solid tumors by activating selectively within the tumor microenvironment while remaining inactive elsewhere.
Werewolf Therapeutics announced the first patient has been dosed in the Phase 1/1b trial for WTX-124, its leading INDUKINE™ molecule targeting IL-2 for treating solid tumors. This multi-center, open-label trial will evaluate WTX-124 alone and with KEYTRUDA® in patients with advanced solid tumors who have not responded to standard care. The innovative design aims to minimize toxicities associated with conventional IL-2 therapy while enhancing anti-tumor activity in the tumor microenvironment. This pivotal milestone reflects Werewolf's commitment to advancing its oncology pipeline.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) reported significant advancements in its clinical development, including FDA clearance for WTX-124, its lead candidate for treating advanced solid tumors. The IND application for WTX-330 is set for submission in 2H22. The company holds a strong cash position of $145.7 million, expected to sustain operations through Q4 2023. Collaboration revenue reached $4.1 million due to an upfront payment from Jazz Pharmaceuticals, though R&D expenses increased to $13.9 million, leading to a net loss of $14.6 million for Q2 2022.
Werewolf Therapeutics (Nasdaq: HOWL) will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9-10, 2022. The company focuses on developing conditionally activated therapeutics to enhance the immune system for cancer treatment. Utilizing its proprietary PREDATOR™ platform, Werewolf aims to create molecules that activate selectively within the tumor microenvironment, minimizing side effects. Key product candidates include WTX-124 and WTX-330, both targeting solid tumors and designed to work with immune checkpoint inhibitors. For more information, visit www.werewolftx.com.
Werewolf Therapeutics (Nasdaq: HOWL), an innovative biopharmaceutical company focused on cancer treatments, announced that Dr. Randi Isaacs, Chief Medical Officer, will participate in a fireside chat at 9:00 AM ET on June 9, 2022, during the Jefferies Global Healthcare Conference in New York. The event is scheduled from June 8-10, 2022. A live webcast will be available, and an archived replay will be accessible for 30 days. Werewolf is pioneering therapeutics that stimulate the immune system using its proprietary PREDATOR™ platform, aiming to enhance treatment for solid tumors.
Werewolf Therapeutics (HOWL) has entered an exclusive global licensing and collaboration agreement with Jazz Pharmaceuticals for WTX-613, an investigational cytokine pro-drug for cancer treatment. The deal includes a $15 million upfront payment and potential milestones totaling $1.26 billion, along with royalties on future sales. Additionally, preclinical data for two lead molecules, WTX-124 and WTX-330, has been presented, supporting their development timelines. As of Q1 2022, Werewolf reported a cash balance of $143.7 million, sufficient to fund operations through at least Q4 2023.
Werewolf Therapeutics (HOWL) presented promising preclinical data on its IL-2 and IL-12 INDUKINE molecules, WTX-124 and WTX-330, at the AACR Annual Meeting. WTX-124 demonstrated high tumor selectivity and significant anti-tumor activity via CD8+ T cells, showing a better therapeutic window than recombinant IL-2. WTX-330 exhibited potent anti-tumor immunity and a notable therapeutic window compared to IL-12. The company plans to file IND applications for both candidates in 2022, with WTX-124 evaluated in collaboration with Merck's KEYTRUDA.